Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma

We report a case showing the long-term clinical benefit of the continued use of gefitinib in a patient with asymptomatic progression of lung adenocarcinoma harboring an exon 19 deletion of the epidermal growth factor receptor gene. Although follow-up studies showed smoldering progression of metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hayoung, Chang, Jinsun, Shin, Hong-Joon, Park, Cheol-Kyu, Oh, In-Jae, Kim, Kyu-Sik, Kim, Young-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448482/
https://www.ncbi.nlm.nih.gov/pubmed/26273363
http://dx.doi.org/10.1111/1759-7714.12171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448482/
https://www.ncbi.nlm.nih.gov/pubmed/26273363
http://dx.doi.org/10.1111/1759-7714.12171

Ejemplares similares